Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group

被引:9
|
作者
Shimada, Y
Akane, H
Taniguchi, N
Matsuhisa, A
Kawano, N
Kikuchi, K
Yatsu, T
Tahara, A
Tomura, Y
Kusayama, T
Wada, K
Tsukada, J
Tsunoda, T
Tanaka, A
机构
[1] Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Tsukuba, Ibaraki 3058585, Japan
[2] Yamanouchi Pharmaceut Co Ltd, Clin Dev Dept, Itabashi Ku, Tokyo 1748612, Japan
[3] Yamanouchi Pharmaceut Co Ltd, Chem Technol Lab, Ibaraki 3180001, Japan
[4] Yamanouchi Pharmaceut Co Ltd, Corp Commun Dept, Chuo Ku, Tokyo 1038411, Japan
关键词
arginine vasopressin; V-1A receptor selective antagonist; 2-ethyl-1H-1-imidazole;
D O I
10.1248/cpb.53.764
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
To find a new series of arginine vasopressin (AV]P) VIA receptor antagonists, the influence of the 2-phenyl group of 2-phenyl-4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanilide (7) was investigated. Replacement of the 2-phenyl group by a 2-ethyl-1H-imidazol-1-yl group was effective in yielding a V-IA-selective compound. Moreover, this imidazolyl group was introduced in the same position in YM-35471 (6), and further studies of these compounds were performed. Consequently, we found that the (Z)-4'-({4,4-difluoro-5-[(N-cyclo-propylcarbamoyl)methylenel-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl}carbonyl)-2-(2-ethyl-1H-1-imidazol-1- yl)benzanilide (9f) exhibited highly potent affinity and selectivity, and was the most potent antagonist for the V,A receptor among our compounds. The synthesis and pharmacological evaluation of these compounds are described in this paper.
引用
收藏
页码:764 / 769
页数:6
相关论文
共 50 条
  • [1] Preparation of non-peptide, highly potent and selective antagonists of arginine vasopressin v1A receptor by introduction of alkoxy groups
    Shimada, Y
    Taniguchi, N
    Matsuhisa, A
    Yatsu, T
    Tahara, A
    Tanaka, A
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2003, 51 (09) : 1075 - 1080
  • [2] Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor
    Shimada, Y
    Taniguchi, N
    Matsuhisa, A
    Akane, H
    Kawano, N
    Suzuki, T
    Tobe, T
    Kakefuda, A
    Yatsu, T
    Tahara, A
    Tomura, Y
    Kusayama, T
    Wada, K
    Tsukada, J
    Orita, M
    Tsunoda, T
    Tanaka, A
    BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (06) : 1827 - 1837
  • [3] 4,4-difluoro-5-methylene-2,3,4,5-tetrahydro-1H-1-benzazepine derivatives: Highly potent and selective antagonists of arginine vasopressin V1A receptor.
    Shimada, Y
    Taniguchi, N
    Matsuhisa, A
    Akane, H
    Kawano, N
    Yatsu, T
    Tanaka, A
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 214 : 203 - MEDI
  • [4] Superimposition of potent non-peptide AT(1) receptor antagonists with angiotensin II
    Theodoropoulou, E
    Mavromoustakos, T
    Panagiotopoulos, D
    Matsoukas, JM
    Smith, J
    LETTERS IN PEPTIDE SCIENCE, 1996, 3 (04): : 209 - 216
  • [5] Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents
    Manning, Maurice
    Stoev, Stoytcho
    Chini, Bice
    Durroux, Thierry
    Mouillac, Bernard
    Guillon, Gilles
    ADVANCES IN VASOPRESSIN AND OXYTOCIN: FROM GENES TO BEHAVIOUR TO DISEASE, 2008, 170 : 473 - 512
  • [6] Identification and SAR of potent and selective non-peptide obeline somatostatin sst1 receptor antagonists
    Troxler, Thomas
    Hoyer, Daniel
    Langenegger, Daniel
    Neumann, Peter
    Pfaeffli, Paul
    Sehoeffter, Philippe
    Sorg, Dieter
    Swoboda, Robert
    Hurth, Konstanze
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (14) : 3983 - 3987
  • [7] Nonpeptide vasopressin receptor antagonists:: development of selective and orally active V1a, V2 and V1b receptor ligands
    Serradeil-Le Gal, C
    Wagnon, J
    Valette, G
    Garcia, G
    Pascal, M
    Maffrand, JP
    Le Fur, G
    VASOPRESSIN AND OXYTOCIN: FROM GENES TO CLINICAL APPLICATIONS, 2002, 139 : 197 - 210
  • [8] Highly potent and orally active non-peptide arginine vasopressin antagonists for both V1A and V2 receptors:: Synthesis and pharmacological properties of 4′-[(4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzoazepin-1-yl)carbonyl]-2-phenylbenzanilide derivatives
    Shimada, Y
    Taniguchi, N
    Matsuhisa, A
    Sakamoto, K
    Yatsu, T
    Tanaka, A
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2000, 48 (11) : 1644 - 1651
  • [9] Bridged bicyclic vasopressin receptor antagonists V2-selective or dual V1a/V2 activity
    Dyatkin, AB
    Hoekstra, WJ
    Hlasta, DJ
    Andrade-Gordon, P
    de Garavilla, L
    Demarest, KT
    Gunnet, JW
    Hagemann, W
    Look, R
    Maryanoff, BE
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (21) : 3081 - 3084
  • [10] Structurally novel V2-selective and dual V1A/V2 vasopressin receptor antagonists.
    Dyatkin, AB
    Maryanoff, BE
    Hoekstra, WJ
    Hlasta, DJ
    Andrade-Gordon, P
    DeGaravilla, L
    Demarest, K
    Gunnet, J
    Look, R
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 223 : A93 - A93